OBJECTIVE: We sought to characterize clinical and pathologic outcomes of advanced mixed germ cell tumors after retroperitoneal lymph node dissection for post-chemotherapy residual masses. MATERIAL AND METHODS: Between January 2006 and November 2015, 56 patients underwent retroperitoneal lymph node dissection (RPLND) for residual masses of greater than 1 cm after receiving either primary chemotherapy or salvage chemotherapy. Retrospective review of the patients' characteristics, clinical, pathological, and treatment outcomes were performed after institutional review board (IRB) and ethics committee approval. RESULTS: The mean age at diagnosis was 30 years. Ninety percent of the patients received 3-4 cycles of BEP (bleomycin/etoposide/cisplatin) as primary chemotherapy, and 29% of them salvage chemotherapy prior to lymph node dissection. The mean size of the residual masses after chemotherapy was 6 cm. The histological findings were necrosis in 30%, viable tumor in 34% and teratoma in 36% of the retroperitoneal masses. The mean time to relapse after RPLND was 11 months, out of 9 relapses, 6 were in the retroperitoneum, 1 in the lung and 1 in the kidney and 1 in the contralateral testicle. CONCLUSION: Our results indicated higher incidence of viable germ cell tumor in the retroperitoneal residual masses after primary and salvage chemotherapy when compared with previously reported global incidence rates.
OBJECTIVE: We sought to characterize clinical and pathologic outcomes of advanced mixed germ cell tumors after retroperitoneal lymph node dissection for post-chemotherapy residual masses. MATERIAL AND METHODS: Between January 2006 and November 2015, 56 patients underwent retroperitoneal lymph node dissection (RPLND) for residual masses of greater than 1 cm after receiving either primary chemotherapy or salvage chemotherapy. Retrospective review of the patients' characteristics, clinical, pathological, and treatment outcomes were performed after institutional review board (IRB) and ethics committee approval. RESULTS: The mean age at diagnosis was 30 years. Ninety percent of the patients received 3-4 cycles of BEP (bleomycin/etoposide/cisplatin) as primary chemotherapy, and 29% of them salvage chemotherapy prior to lymph node dissection. The mean size of the residual masses after chemotherapy was 6 cm. The histological findings were necrosis in 30%, viable tumor in 34% and teratoma in 36% of the retroperitoneal masses. The mean time to relapse after RPLND was 11 months, out of 9 relapses, 6 were in the retroperitoneum, 1 in the lung and 1 in the kidney and 1 in the contralateral testicle. CONCLUSION: Our results indicated higher incidence of viable germ cell tumor in the retroperitoneal residual masses after primary and salvage chemotherapy when compared with previously reported global incidence rates.
Authors: K Fizazi; S Tjulandin; R Salvioni; J R Germà-Lluch; J Bouzy; D Ragan; C Bokemeyer; A Gerl; A Fléchon; J S de Bono; S Stenning; A Horwich; J Pont; P Albers; U De Giorgi; M Bower; A Bulanov; G Pizzocaro; J Aparicio; C R Nichols; C Théodore; J T Hartmann; H J Schmoll; S B Kaye; S Culine; J P Droz; C Mahé Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: Brett S Carver; Fernando J Bianco; Bobby Shayegan; Andrew Vickers; Robert J Motzer; George J Bosl; Joel Sheinfeld Journal: J Urol Date: 2006-07 Impact factor: 7.450
Authors: Yvonne Vergouwe; Ewout W Steyerberg; Richard S Foster; Dirk T Sleijfer; Sophie D Fosså; Arthur Gerl; Ronald de Wit; J Trevor Roberts; J Dik F Habbema Journal: Eur Urol Date: 2006-07-14 Impact factor: 20.096
Authors: Bobby Shayegan; Brett S Carver; Jason Stasi; Robert J Motzer; George J Bosl; Joel Sheinfeld Journal: BJU Int Date: 2007-05 Impact factor: 5.588
Authors: Robert J Motzer; Eric Jonasch; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Sam S Chang; Toni K Choueiri; Brian A Costello; Ithaar H Derweesh; Shilpa Gupta; Steven L Hancock; Jenny J Kim; Timothy M Kuzel; Elaine T Lam; Clayton Lau; Ellis G Levine; Daniel W Lin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Elizabeth R Plimack; Edward N Rampersaud; Bruce G Redman; Charles J Ryan; Joel Sheinfeld; Brian Shuch; Kanishka Sircar; Brad Somer; Richard B Wilder; Mary Dwyer; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2015-06 Impact factor: 11.908
Authors: E W Steyerberg; H J Keizer; S D Fosså; D T Sleijfer; G C Toner; H Schraffordt Koops; P F Mulders; J E Messemer; K Ney; J P Donohue Journal: J Clin Oncol Date: 1995-05 Impact factor: 44.544